AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL

NCT ID: NCT01278420

Last Updated: 2012-06-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the visual outcomes with bilateral implantation of Tecnis MF and ReSTOR IOLs Six months post cataract surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to compare the visual outcomes with bilateral implantation of Tecnis MF and ReSTOR IOLs Six months post cataract surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tecnis MF

Group Type OTHER

Tecnis MF

Intervention Type DEVICE

30 subjects will be implanted with the Tecnis MF

ReSTOR

Group Type OTHER

ReSTOR

Intervention Type DEVICE

30 subjects will be implanted with ReSTOR

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tecnis MF

30 subjects will be implanted with the Tecnis MF

Intervention Type DEVICE

ReSTOR

30 subjects will be implanted with ReSTOR

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or greater
* Bilateral condition (cataracts or Presbyopia) for which phacoemulsification and posterior IOL implantation has been planned for both eyes
* Visual potential of 20/25 or better in each eye after cataract removal and IOL implantation
* Clear intraocular media other than cataract
* Normal OCT of the macula
* No evidence of Keratoconus or significant irregular astigmatism on Preoperative topography
* No evidence of Epithelial Basement Membrane Dystrophy on Slit lamp Exam
* Availability, willingness, and sufficient cognitive awareness to comply with examination procedures

Exclusion Criteria

* Use of systemic or ocular medications that may affect vision
* Uncontrolled systemic or ocular disease
* History of ocular trauma
* History of intraocular, extraocular Muscle, or corneal surgery (including laser vision correction)
* Amblyopia or strabismus
* Known pathology that may affect visual acuity; particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.)
* Diagnosed degenerative visual disorders (e.g. macular degeneration, or other retinal disorders) that are predicted to cause future acuity losses to a level of 20/25 or worse
* Subjects who may be expected to require retinal laser treatment or other surgical intervention (i.e patients with diabetic retinopathy)
* Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome)
* Contact lens usage within 2 months for PMMA contacts lenses, 2 weeks for gas permeable lenses or 3 days for extended-wear and daily-wear soft contact lenses
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Innovative Medical

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

The Center for Excellence in Eye Care

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William Trattler, MD

Role: PRINCIPAL_INVESTIGATOR

The Center for Excellence in Eye Care

Mitch Jackson, MD

Role: PRINCIPAL_INVESTIGATOR

Jackson Eye

Larry Katzen, MD

Role: PRINCIPAL_INVESTIGATOR

Katzen Eye Care & Laser Center

Kevin Waltz, MD

Role: PRINCIPAL_INVESTIGATOR

Eye Surgeons of Indiana

Shamik Bafna, MD

Role: PRINCIPAL_INVESTIGATOR

Clevland Eye Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sansum- Santa Barbara medical foundation Clinic

Santa Barbara, California, United States

Site Status ACTIVE_NOT_RECRUITING

Katzen Eye Care & Laser Center

Boynton Beach, Florida, United States

Site Status RECRUITING

The Center for Excellence in Eye Care

Miami, Florida, United States

Site Status RECRUITING

Jackson Eye, SC

Lake Villa, Illinois, United States

Site Status RECRUITING

Eye Surgeons of Indiana

Indianapolis, Indiana, United States

Site Status RECRUITING

Cleveland Eye Clinic

Breckville, Ohio, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jenna Piel

Role: CONTACT

951-653-5566

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TMF vs Restor MF 3D

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.